+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Schizophrenia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 185 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5925042
Schizophrenia, a chronic disorder that profoundly impacts individuals' lives, is characterized by an abnormal interpretation of reality and leads to various behavioral changes, including hallucinations and delusions. Schizophrenia treatment is an ongoing journey, with medications playing a pivotal role in controlling patients' behavior by regulating dopamine levels in the brain.

Advancements in Treatment

Antipsychotic medications, particularly second-generation antipsychotics, are commonly prescribed due to their reduced side effects compared to first-generation counterparts. In addition to medication, schizophrenia is also addressed through therapies such as individual therapy and social skill therapy, enhancing the quality of life for individuals living with schizophrenia.

Global Market Insights

A comprehensive research report on the global schizophrenia treatment market explores various therapies and their market scenarios across different regions. The report delves into trends, drivers, challenges, and opportunities shaping the landscape. According to the research, the global schizophrenia treatment market is poised for robust expansion in the coming years.

The Burden of Schizophrenia

According to the World Health Organization, approximately 50 million people worldwide are affected by schizophrenia. Despite a declining prevalence rate, the diagnosis and prescription rates for this disorder continue to rise, creating substantial growth prospects for schizophrenia treatment.

The increasing rate of diagnosis can be attributed to a growing number of patients seeking treatment. Since the introduction of the first atypical antipsychotic treatment for schizophrenia in 1970, the pursuit of treatment has significantly increased, thanks to the reduced side effects associated with atypical psychotic medications.

Collaborative Efforts Drive Market Growth

Key players in the schizophrenia treatment market are actively forging commercialization and research alliances to seize opportunities. Collaborations and partnerships have proven to be more effective than mergers and acquisitions, yielding immediate positive impacts. Manufacturers of schizophrenia medications are also exploring emerging markets as avenues for revenue generation.

Atypical Antipsychotics Take the Lead

Among the various medications available for schizophrenia, atypical antipsychotic treatment, a second-generation medication, stands out for its effectiveness and fewer side effects. The atypical antipsychotics segment is projected to experience high growth during the forecast period.

Miscellaneous antipsychotic agents, including lithium, pimozide, molindone, haloperidol, and loxapine, are also gaining traction. Physicians often opt for haloperidol and lithium due to their effectiveness and competitive pricing. The miscellaneous antipsychotic agents segment is expected to expand at a value CAGR of 6.1% throughout the assessment period.

As the global schizophrenia treatment market continues to evolve, it holds the promise of transforming the lives of individuals affected by this challenging disorder. The focus on innovative treatments and collaborative efforts reflects the commitment of stakeholders to improve the well-being and outlook for those living with schizophrenia.

Schizophrenia Treatment Market Segmentation:

By Product Type

  • Atypical Antipsychotics
  • Phenothiazine Antipsychotics
  • Thioxanthenes
  • Miscellaneous Antipsychotic Agents

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East and Africa (MEA)


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Schizophrenia Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Schizophrenia Treatment Market Outlook, 2018 - 2031
3.1. Global Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Atypical Antipsychotics
3.1.1.2. Phenothiazine Antipsychotics
3.1.1.3. Thioxanthenes
3.1.1.4. Miscellaneous Antipsychotic Agents
3.2. Global Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Hospital Pharmacies
3.2.1.2. Drug Stores
3.2.1.3. Retail Pharmacies
3.2.1.4. E-Commerce
3.3. Global Schizophrenia Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Schizophrenia Treatment Market Outlook, 2018 - 2031
4.1. North America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Atypical Antipsychotics
4.1.1.2. Phenothiazine Antipsychotics
4.1.1.3. Thioxanthenes
4.1.1.4. Miscellaneous Antipsychotic Agents
4.2. North America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospital Pharmacies
4.2.1.2. Drug Stores
4.2.1.3. Retail Pharmacies
4.2.1.4. E-Commerce
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
4.3.1.2. U.S. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.3.1.3. Canada Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
4.3.1.4. Canada Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Schizophrenia Treatment Market Outlook, 2018 - 2031
5.1. Europe Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Atypical Antipsychotics
5.1.1.2. Phenothiazine Antipsychotics
5.1.1.3. Thioxanthenes
5.1.1.4. Miscellaneous Antipsychotic Agents
5.2. Europe Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospital Pharmacies
5.2.1.2. Drug Stores
5.2.1.3. Retail Pharmacies
5.2.1.4. E-Commerce
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Germany Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.2. Germany Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.3. U.K. Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.4. U.K. Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.5. France Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.6. France Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.7. Italy Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.8. Italy Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.9. Turkey Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.10. Turkey Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.11. Russia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.12. Russia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.1.13. Rest of Europe Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
5.3.1.14. Rest of Europe Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Schizophrenia Treatment Market Outlook, 2018 - 2031
6.1. Asia Pacific Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Atypical Antipsychotics
6.1.1.2. Phenothiazine Antipsychotics
6.1.1.3. Thioxanthenes
6.1.1.4. Miscellaneous Antipsychotic Agents
6.2. Asia Pacific Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospital Pharmacies
6.2.1.2. Drug Stores
6.2.1.3. Retail Pharmacies
6.2.1.4. E-Commerce
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. China Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.2. China Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1.3. Japan Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.4. Japan Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1.5. South Korea Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.6. South Korea Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1.7. India Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.8. India Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1.9. Southeast Asia Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.10. Southeast Asia Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.1.11. Rest of Asia Pacific Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
6.3.1.12. Rest of Asia Pacific Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Schizophrenia Treatment Market Outlook, 2018 - 2031
7.1. Latin America Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Atypical Antipsychotics
7.1.1.2. Phenothiazine Antipsychotics
7.1.1.3. Thioxanthenes
7.1.1.4. Miscellaneous Antipsychotic Agents
7.2. Latin America Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Hospital Pharmacies
7.2.1.2. Drug Stores
7.2.1.3. Retail Pharmacies
7.2.1.4. E-Commerce
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
7.3.1.2. Brazil Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.3.1.3. Mexico Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
7.3.1.4. Mexico Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.3.1.5. Argentina Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
7.3.1.6. Argentina Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.3.1.7. Rest of Latin America Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
7.3.1.8. Rest of Latin America Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Schizophrenia Treatment Market Outlook, 2018 - 2031
8.1. Middle East & Africa Schizophrenia Treatment Market Outlook, by Product Type, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Atypical Antipsychotics
8.1.1.2. Phenothiazine Antipsychotics
8.1.1.3. Thioxanthenes
8.1.1.4. Miscellaneous Antipsychotic Agents
8.2. Middle East & Africa Schizophrenia Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospital Pharmacies
8.2.1.2. Drug Stores
8.2.1.3. Retail Pharmacies
8.2.1.4. E-Commerce
8.3. Middle East & Africa Schizophrenia Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. GCC Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
8.3.1.2. GCC Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.1.3. South Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
8.3.1.4. South Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.1.5. Egypt Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
8.3.1.6. Egypt Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.1.7. Nigeria Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
8.3.1.8. Nigeria Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.1.9. Rest of Middle East & Africa Schizophrenia Treatment Market by Product Type, Value (US$ Mn), 2018 - 2031
8.3.1.10. Rest of Middle East & Africa Schizophrenia Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by Distribution Channel Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Johnson & Johnson Services, Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Bristol-Myers Squibb Company
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Otsuka Holdings Co., Ltd
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. AstraZeneca
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Sumitomo Dainippon Pharma Co., Ltd.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Eli Lilly and Company
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Alkermes
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Vanda Pharmaceuticals
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. ALLERGAN
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Pfizer Inc.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Otsuka Holdings Co., Ltd
  • AstraZeneca
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Eli Lilly and Company
  • Alkermes
  • Vanda Pharmaceuticals
  • ALLERGAN
  • Pfizer Inc.

Methodology

Loading
LOADING...